WAMD: From Pathophysiology to Therapeutic Treatment 2.0

Dear Colleagues,

In this Special Issue on wet age-related macular degeneration (wAMD), we would like to explore new wAMD strategies to achieve better visual acuity and retina structural outcomes. Age-related macular degeneration is one of the main causes of visual impairment in elderly people. While the dry form has no approved treatment, several therapies have been proposed for the wAMD form to try to change the course of the disease and to improve visual acuity. The main treatments for wAMD are based on targeting choroidal neovascular membranes. The anti-VEGF agents have dramatically improved the disease outcome. In this issue, we are especially interested in examining consolidated and new anti-VEGF therapies and also considering the treatment protocols. Potential topics will include:

• Aflibercept, ranibizumab and brolucizumab treatment regimen
• Clinical trials for new drugs development
• Different types of wAMD and related disease outcomes
• Possible application of telemedicine in wAMD diagnosis and follow-up
• Nutritional supplements in wAMD

Dr. Francesca Toja
Dr. Stefano Lupo
Dr. Enzo Maria Vingolo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.